Stage II-IIIA Non Small Cell Lung Cancer? Buy Time with Mix of Therapies

Share Button

“The targeted therapy gefitinib appears more effective in preventing recurrence after lung cancer surgery than the standard of care, chemotherapy”

A lung cancer diagnosis of stage 2 or 3 is not about one procedure to cure or not cure the patient. My experience as a long-term survivor of an incurable cancer is that each patient must combine the most effective therapies of both conventional (FDA approved) and evidence-based non-conventional therapies to most effectively treat their cancer for the long-term.

Make no mistake. Lung cancer is an aggressive cancer. If you are staged at 2 or 3 then “the five-year survival for patients with stage II-IIIA NSCLC is only 40 percent.. ” The study linked and excerpted below talks about a conventional therapy that can buy you time to undergo evidence-based, non-conventional therapies. Which in turn may buy you more time…

Treating Lung Cancer With Surgery

Surgery to remove as much of the lung cancer as possible is the first step in managing your cancer. However, chances are, your cancer will relapse. Many cancers do. My point is to anticipate this relapse and take the steps necessary to work with this possibility.

I have been “buying more time” from my “incurable cancer” since 1999.  When my oncologist told me that there was nothing more that she could do for me in September of 1997, I decided to undergo a controversial non-conventional cancer therapy. I reached complete remission by early 1999.

Survivors of my cancer, multiple myeloma, always relapse. Therefore I consider the evidence-based, non-toxic therapies I do each day to be buying time until I relapse. One day at a time…

Have you been diagnosed with lung cancer? What stage? What therapies have you undergone? Please scroll down the page, post a question or comment and I will reply to you ASAP.

Thank you,

David Emerson

  • Cancer Survivor
  • Cancer Coach
  • Director PeopleBeatingCancer

targeted therapy can delay recurrence of intermediate-stage lung cancer

“The targeted therapy gefitinib appears more effective in preventing recurrence after lung cancer surgery than the standard of care, chemotherapy…

In a phase III clinical trial, patients with epidermal growth factor receptor (EGFR)-positive, stage II-IIIA non-small cell lung cancer (NSCLC) who received gefitinib (Irressa) went about 10 months longer without recurrence than patients who received chemotherapy…

Due to high chance of recurrence, the five-year survival for patients with stage II-IIIA NSCLC is only 40 percent. About 25 percent of all patients who are diagnosed with NSCLC are eligible to have surgery to remove the tumors with the hope of a cure. Among that group, about 30 percent or 140,000 people worldwide have an EGFR mutation in the tumor and may benefit from adjuvant treatment with EGFR-targeted therapy to reduce the chance of recurrence

 

About

David Emerson is a 23 year Multiple Myeloma survivor. He started PeopleBeatingCancer.org as a non-profit in 2004 to help cancer survivors and caregivers navigate the vast world of cancer issues by providing evidence-based information on the most pressing cancer issues. Since 2004, David has impacted over 600,000 people through this website. He is in the process of developing cancer-specific coaching program, and also does one-on-one coaching via phone or email. Thank you for visiting!

Posted in non-conventional therapies Tagged with:

Leave a Reply

Your email address will not be published. Required fields are marked *

*